Grant: Fellowship - PA: Regional Partnership Program - Manitoba
University of Manitoba
$45,000.00
Regulation of Anti-Leishmania Immunity by CD3+CD4-CD8- (Double Negative) T Cells.
EF 2011-12
Résumé
Leishmaniases are parasitic diseases that affect both humans and animals. It is caused by protozoan parasite belonging to the genus Leishmania. The disease is endemic in 88 countries and it is currently estimated by WHO that about 12 million people worldwide are afflicted with the disease with more than1.5 - 2 million new cases occurring every year and 350 million at risk of infection. There is no effective vaccine against leishmaniasis and the current treatments are very expensive, highly toxic and there are increasing reports of development of drug resistance. Although, the disease occurs mostly in the tropics and subtropics, increased travel, globalization and war, has resulted in the presence of the disease in individuals from endemic areas. For instance, Canadian and American Soldiers returning from active duty in the endemic areas like Iraq and Afghanistan have been diagnosed with the disease. Vaccination remains the most cost-effective means of controlling infectious diseases. Unfortunately, there is still no effective vaccine against leishmaniasis. This is in part related to our lack of understanding of the factors that regulate immunologic memory; which is the ability of our defense system to recognize pathogens it has successfully dealt with and to make those protective molecules faster during a subsequent exposure. Any effective vaccine should lead to the development of cells called memory cells that will protect vaccinated individuals upon subsequent exposure to the infectious agent (immunologic memory). This project will investigate the part a newly described cell population plays in the development and maintenance of immunologic memory in cutaneous leishmaniasis. Results from this study will extend our knowledge and understanding of the factors that regulate memory cell development in leishmaniasis and could aid understanding of other infectious diseases like HIV, malaria and tuberculosis
Programme
Fellowship - PA: Regional Partnership Program - Manitoba
Bénéficiaire
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
259720
Name
Gao xiaoling
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Manitoba Health Research Council
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Regulation of Anti-Leishmania Immunity by CD3+CD4-CD8- (Double Negative) T Cells.
Programtype2
Fellowship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - PA: Regional Partnership Program - Manitoba
Keyworddelim
Immonologic Memory; Immunology; Infection And Immunity; Infectious Disease; Parasitic Disease
Abstract
Leishmaniases are parasitic diseases that affect both humans and animals. It is caused by protozoan parasite belonging to the genus Leishmania. The disease is endemic in 88 countries and it is currently estimated by WHO that about 12 million people worldwide are afflicted with the disease with more than1.5 - 2 million new cases occurring every year and 350 million at risk of infection. There is no effective vaccine against leishmaniasis and the current treatments are very expensive, highly toxic and there are increasing reports of development of drug resistance. Although, the disease occurs mostly in the tropics and subtropics, increased travel, globalization and war, has resulted in the presence of the disease in individuals from endemic areas. For instance, Canadian and American Soldiers returning from active duty in the endemic areas like Iraq and Afghanistan have been diagnosed with the disease. Vaccination remains the most cost-effective means of controlling infectious diseases. Unfortunately, there is still no effective vaccine against leishmaniasis. This is in part related to our lack of understanding of the factors that regulate immunologic memory; which is the ability of our defense system to recognize pathogens it has successfully dealt with and to make those protective molecules faster during a subsequent exposure. Any effective vaccine should lead to the development of cells called memory cells that will protect vaccinated individuals upon subsequent exposure to the infectious agent (immunologic memory). This project will investigate the part a newly described cell population plays in the development and maintenance of immunologic memory in cutaneous leishmaniasis. Results from this study will extend our knowledge and understanding of the factors that regulate memory cell development in leishmaniasis and could aid understanding of other infectious diseases like HIV, malaria and tuberculosis
Competitiondate
201202
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Gao, xiaoling
Approvedterm
2 ans 0 mois
Cihrcontribution2
SPIR~ $45,000~ $0~